nutrients-logo

Journal Browser

Journal Browser

Phytomedicine, Mediterranean Diet and Prevention of Aging and Age-Related Diseases

A special issue of Nutrients (ISSN 2072-6643). This special issue belongs to the section "Phytochemicals and Human Health".

Deadline for manuscript submissions: closed (15 January 2024) | Viewed by 4832

Special Issue Editors


E-Mail
Guest Editor
1. Department of Pharmacology and Physiology, Faculty of Medicine, University de Montréal, Montreal, QC H3T 1A8, Canada
2. Faculty of Sciences and Techniques, Errachidia, Moulay Ismail University of Meknes, Meknes 50050, Morocco
Interests: type 2 diabetes; hypertension; obesity; oxidative stress; anti-oxidants; argan oil
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Team "Biochemistry of the Peroxisome, Inflammation and Lipid Metabolism", Université de Bourgogne Franche-Comté, 21000 Dijon, France
Interests: lipids; oxysterols; fatty acids; polyphenols; oils; oxidation; inflammation; mitochondria; peroxisomes; lysosomes; apoptosis; autophagy; natural products; synthethic molecules; biomarkers; neurodegeneration; neurodegenerative diseases; aging; age-related diseases; nanoparticles; targeted therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It is a great pleasure to welcome you to contribute to this Special Issue of  Nutrients, which will be released as part of the First International Conference on “Phytomedicine, Mediterranean Diet and Prevention of Aging and Age-Related Diseases”.

The conference and forthcoming papers will serve as an international forum for the presentation and discussion of current basic and clinical research in the field of phytomedicine and the Mediterranean diet.

This Special Issue of Nutrients, entitled “Phytomedicine, Mediterranean Diet and Prevention of Aging and Age-Related Diseases,” aims to highlight the nutritional and therapeutic properties of argan oil, saffron, thyme and their nutrients as well as the Mediterranean diet’s role in the prevention of aging and in the treatment and prevention of various age-related diseases and diseases of civilization. We are seeking articles from outstanding experts in the following fields: cardiovascular diseases, hypertension, type 2 diabetes, ocular diseases, metabolic syndrome, obesity, neurodegenerative diseases (Alzheimer’s, Parkinson’s), cancer and others.

Dr. Adil El Midaoui
Dr. Gérard Lizard
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nutrients is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mediterranean diet
  • aging
  • age-related diseases
  • argan oil
  • natural products

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 4271 KiB  
Article
Anti-Inflammatory, Analgesic, Functional Improvement, and Chondroprotective Effects of Erigeron breviscapus (Vant.) Hand.-Mazz. Extract in Osteoarthritis: An In Vivo and In Vitro Study
by Hee-Geun Jo, Chae Yun Baek, JunI Lee, Yeseul Hwang, Eunhye Baek, Ji Hye Hwang and Donghun Lee
Nutrients 2024, 16(7), 1035; https://doi.org/10.3390/nu16071035 - 02 Apr 2024
Viewed by 728
Abstract
Osteoarthritis (OA) is a degenerative bone disease characterized by inflammation as a primary pathology and currently lacks therapeutic interventions to impede its progression. Erigeron breviscapus (Vant.) Hand.-Mazz. (EB) is an east Asian herbal medicine with a long history of use and a wide [...] Read more.
Osteoarthritis (OA) is a degenerative bone disease characterized by inflammation as a primary pathology and currently lacks therapeutic interventions to impede its progression. Erigeron breviscapus (Vant.) Hand.-Mazz. (EB) is an east Asian herbal medicine with a long history of use and a wide range of confirmed efficacy against cardiovascular and central nervous system diseases. The purpose of this study is to evaluate whether EB is worthy of further investigation as a treatment for OA based on anti-inflammatory activity. This study aims to assess the potential of EB as a treatment for OA, focusing on its anti-inflammatory properties. Analgesic effects, functional improvements, and inhibition of cartilage destruction induced by EB were evaluated in acetic acid-induced peripheral pain mice and monosodium iodoacetate-induced OA rat models. Additionally, the anti-inflammatory effect of EB was assessed in serum and cartilage tissue in vivo, as well as in lipopolysaccharide-induced RAW 264.7 cells. EB demonstrated a significant alleviation of pain, functional impairment, and cartilage degradation in OA along with a notable inhibition of pro-inflammatory cytokines, including interleukin-1β, interleukin-6, matrix metalloproteinases 13, and nitric oxide synthase 2, both in vitro and in vivo, in a dose-dependent manner compared to the active control. Accordingly, EB merits further exploration as a potential disease-modifying drug for OA, capable of mitigating the multifaceted pathology of osteoarthritis through its anti-inflammatory properties. Nonetheless, additional validation through a broader experimental design is essential to substantiate the findings of this study. Full article
Show Figures

Figure 1

19 pages, 3605 KiB  
Article
KYMASIN UP Natural Product Inhibits Osteoclastogenesis and Improves Osteoblast Activity by Modulating Src and p38 MAPK
by Laura Salvadori, Maria Laura Belladonna, Beatrice Castiglioni, Martina Paiella, Eleonora Panfili, Tommaso Manenti, Catia Ercolani, Luca Cornioli, Sara Chiappalupi, Giulia Gentili, Massimiliano Leigheb, Guglielmo Sorci, Michela Bosetti, Nicoletta Filigheddu and Francesca Riuzzi
Nutrients 2022, 14(15), 3053; https://doi.org/10.3390/nu14153053 - 25 Jul 2022
Cited by 3 | Viewed by 3152
Abstract
The imbalance in osteoblast (OB)-dependent bone formation in favor of osteoclast (OC)-dependent bone resorption is the main cause of loss of tissue mineral mass during bone remodeling leading to osteoporosis conditions. Thus, the suppression of OC activity together with the improvement in the [...] Read more.
The imbalance in osteoblast (OB)-dependent bone formation in favor of osteoclast (OC)-dependent bone resorption is the main cause of loss of tissue mineral mass during bone remodeling leading to osteoporosis conditions. Thus, the suppression of OC activity together with the improvement in the OB activity has been proposed as an effective therapy for maintaining bone mass during aging. We tested the new dietary product, KYMASIN UP containing standardized Withania somnifera, Silybum marianum and Trigonella foenum-graecum herbal extracts or the single extracts in in vitro models mimicking osteoclastogenesis (i.e., RAW 264.7 cells treated with RANKL, receptor activator of nuclear factor kappa-Β ligand) and OB differentiation (i.e., C2C12 myoblasts treated with BMP2, bone morphogenetic protein 2). We found that the dietary product reduces RANKL-dependent TRAP (tartrate-resistant acid phosphatase)-positive cells (i.e., OCs) formation and TRAP activity, and down-regulates osteoclastogenic markers by reducing Src (non-receptor tyrosine kinase) and p38 MAPK (mitogen-activated protein kinase) activation. Withania somnifera appears as the main extract responsible for the anti-osteoclastogenic effect of the product. Moreover, KYMASIN UP maintains a physiological release of the soluble decoy receptor for RANKL, OPG (osteoprotegerin), in osteoporotic conditions and increases calcium mineralization in C2C12-derived OBs. Interestingly, KYMASIN UP induces differentiation in human primary OB-like cells derived from osteoporotic subjects. Based on our results, KYMASIN UP or Withania somnifera-based dietary supplements might be suggested to reverse the age-related functional decline of bone tissue by re-balancing the activity of OBs and OCs, thus improving the quality of life in the elderly and reducing social and health-care costs. Full article
Show Figures

Graphical abstract

Back to TopTop